Immune function, mitogenicity and angiogenic growth factor concentrations in lean and obese rodent sera: Implications in obesity related prostate tumor biology

Prostate Cancer and Prostatic Diseases

Volumn 6, Issue 4, 2003, Pages 286-289

  Mydlo, J H ^a,b   Gerstein, M I ^a   Harris, C F ^a   Braverman, A S ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TEMPLE UNIVERSITY HOSPITAL   (United States)

Author keywords

Angiogenesis; Growth factors; Immunity; Obesity; Tumor

Indexed keywords

ANGIOGENIC FACTOR; BASIC FIBROBLAST GROWTH FACTOR; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; VASCULOTROPIN;

ANIMAL EXPERIMENT; ARTICLE; CANCER INCIDENCE; CANCER INHIBITION; CELL PROLIFERATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNE FUNCTION TEST; INTERMETHOD COMPARISON; LEAN BODY WEIGHT; LIPID DIET; MACROPHAGE FUNCTION; MITOGENICITY; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROSTATE TUMOR; RAT; RAT STRAIN; TUMOR GROWTH;

ANGIOGENESIS INDUCING AGENTS; ANIMALS; CELL DIVISION; CELL LINE, TUMOR; FEMALE; FIBROBLAST GROWTH FACTOR 2; HUMANS; MACROPHAGE INFLAMMATORY PROTEIN-1; MALE; MITOGENS; OBESITY; PROSTATIC NEOPLASMS; RATS; RATS, ZUCKER; TETRAHYDROISOQUINOLINES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 0346007952     PISSN: 13657852     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.pcan.4500693     Document Type: Article

References (21)

1. Mydlo JH, Kanter JL, Kral JG, Macchia RJ. Obesity, diet and other factors in urological malignancies. A review. BJU Int 1999; 86: 1-6.
2. Moller H, Mellemgaard A, Lindvig K, Olsen JH. Obesity and cancer risk: A Danish record-linkage study. Eur J Cancer 1994; 30A: 344-350.
3. Heber D, Fair WR, Ornish D Nutrition and Prostate Cancer. CaPCURE Nutrition Project Monograph, 2nd edn. CaPCURE, Santa Monica 1998.
4. Saxe GA et al. Can diet in conjunction with stress reduction affect the rate of increase in prostate specific antigen after biochemical recurrence of prostate cancer? J Urol 2002; 166: 2202-2207.
5. Mydlo JH, Kral JG, Macchia RJ. Differences in prostate and adipose tissue basic fibroblast growth factor (FGF-2) analysis of preliminary results. Urology 1997; 50: 265-279.
6. Weber RV, Stein DE, Scholes J, Kral JG. Obesity potentiates AOM-induced colon cancer. Digest Dis Sci 2000; 45: 890-895.
7. Mydlo JH et al. A pilot study examining body mass index, serum lipids, PSA, Gleason score and race in men with and without prostate cancer. Prostate Cancer P D 2001; 4: 1-5.
8. Wang Y et al. Decreased growth of established human prostate LNCaP tumors in nude mice fed a low fat diet. J Natl Cancer Inst 1995; 87: 1456-1467.
9. Pienta KJ, Goodson JA, Esper PS. Epidemiology of prostate cancer: molecular and environmental clues. Urology 1996; 48: 676-683.
10. Nataabe H et al. Elevated levels of an angiogenic peptide basic FGF in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst 1994; 86: 356-364.
11. Nanus DM et al. Expression of bFGF in primary human renal tumors and correlation with poor survival. J Natl Cancer Inst 1993; 85: 1597-1605.
12. Mydlo JH et al. Heparin-binding growth factor isolated from human prostatic extracts. The Prostate 1988; 12: 343-355.
13. Folkman J. What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 1990; 82: 4-10.
14. Dirix LY et al. Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients. Br J Cancer 1997; 76: 238-242.
15. Chandra RK. Graying of the immune system. JAMA 1997; 277: 1398-1399.
16. Costello RT, Gastaut JA, Olive D. Tumor escape from immune surveillance. Arch Immuno Ther Exp 1999; 47: 83-88.
17. Roberts RE, Kaplan GA, Shema SJ, Strawbridge WJ. Are the obese at greater risk for depression? Am J Epidemiol 2000; 152: 163-170.
18. Irwin M et al. Impaired natural killer cell activity during bereavement. Brain Behav Immunity 1987; 1: 98-104.
19. Ben-Eliyahu S, Page GG, Yirmiya R, Shakhar G. Evidence that stress and surgical interventions promote tumor development by suppressing natural killer cell activity. Int J Cancer 1999; 80: 880-888.
20. Svane IM, Boesen M, Engel AM. The role of cytotoxic T-lymphocytes in the prevention and immune surveillance of tumors - lessons from normal and immunodeficient mice. Med Oncol 1999; 16: 223-238.
21. Maral J, Florentin I, Soubrane C, Maral R. Cancer and immunosuppression: experimental aspects. Bull Cancer 1983; 70: 351-371.